OUR WEBSITE IS CURRENTLY UNDERGOING A REBUILD AND WILL BE LAUNCHED SHORTLY.

DURING THIS PERIOD IF YOU WISH TO CONTACT US PLEASE USE THIS EMAIL

L3 Technology Limited

L3 Technology Limited (L3T), a privately held UK company, has developed and patented technologies for use in microfluidic applications.  The Company’s primary focus is on developing an in-vitro diagnostic point of care (POC) platform that is suitable for use in a range of clinical settings; from hospital emergency rooms and intensive care units, to physician offices, wellness clinics and pharmacies through to home use.  The platform has the ability to perform fluoresence and / or turbidimetric based assays.

Proof of concept studies have been completed to demonstrate the platform’s potential capabilities using assays for Total Cholesterol, Total Lipid, bacterial enzymes and other analytes. The Company is currently developing a hand-held reader and expects the new prototypes to be available for demonstration by October 2011.

       Reaction Channels              Reagent Depositions (100x)                 Reagent Card

Enabling Technologies and Know How

The L3 Technology (L3T) platform comprises the following technologies:

·            Amphipathic Polymers. A patented solution that enhances microfluidic control.  These polymers are incorporated into analyte specific reagents prior to their deposition onto L3T’s Reagent Card channels.  In use, the polymer construct encourages reagent resolution, sample flow across the channel and mixing of sample with reagent.

·            Microfluidic Card Designs.  Currently there are two card formats designed for use with fluoresence and turbidimetric assays.  Each card contains a sample port with an integral cell separator,  which provides access to four reaction channels.

·            Reagent Cards.  Microfluidic cards are printed with analyte specific reagents or controls in up to four channels  to provide single or multiple test results from a single sample application.

·            Reader.  The Reagents Cards will be read by customised readers that can detect reactions in each channel and provide results within minutes.  Assay time will vary slightly with analyte, but those evaluated to date require less than five minutes from sample addition to result.  The Company is currently miniaturising the bench top “bread board” reader to a hand-held prototype.

·            Lipid Fluorescence Technology.  The Company has patented the use of a series of known and newly synthesised luminophores that partition into specific molecules and thereby create a fluorescent product. Neither the luminophore nor the target molecule will fluoresce in its native state. With appropriate calibration, the fluorescence signal can be converted to an accurate measurement of the analyte present in the sample.